botulinum toxin type A Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5368 None

Description:

MoleculeDescription

Synonyms:

  • botulinum toxin type A
  • nuceiva
Botulinum toxin type A (Clostridium botulinum neurotoxin) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings, thereby leading to denervation of the muscle and a flaccid paralysis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2019 EMA Evolus Pharma Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 21988.15 21.85 12633 53538 665205 45954686
Product preparation error 7240.22 21.85 1565 64606 2474 46617417
Therapeutic response decreased 6827.23 21.85 2485 63686 40660 46579231
Off label use 5554.12 21.85 4426 61745 375415 46244476
Eyelid ptosis 4954.92 21.85 1247 64924 4941 46614950
Wrong technique in product usage process 3865.24 21.85 1767 64404 52655 46567236
Multiple use of single-use product 2399.89 21.85 460 65711 191 46619700
Injection site pain 2271.47 21.85 1573 64598 105579 46514312
Facial paresis 1361.14 21.85 391 65780 2777 46617114
Brow ptosis 953.83 21.85 182 65989 69 46619822
Poor quality product administered 817.55 21.85 261 65910 2748 46617143
Injection site swelling 667.09 21.85 511 65660 39816 46580075
Dysphagia 662.38 21.85 674 65497 76638 46543253
Drug ineffective for unapproved indication 639.29 21.85 356 65815 16057 46603834
Product storage error 595.18 21.85 304 65867 11488 46608403
Swelling face 577.78 21.85 528 65643 52531 46567360
Eye swelling 569.77 21.85 355 65816 19748 46600143
Product preparation issue 553.39 21.85 126 66045 281 46619610
Muscular weakness 551.90 21.85 665 65506 91179 46528712
Eyelid oedema 468.18 21.85 248 65923 10109 46609782
Botulism 401.81 21.85 82 66089 77 46619814
Vision blurred 365.32 21.85 505 65666 79203 46540688
Diarrhoea 332.99 21.85 191 65980 559411 46060480
Migraine 321.34 21.85 444 65727 69582 46550309
Skin wrinkling 308.05 21.85 93 66078 799 46619092
Facial asymmetry 304.32 21.85 86 66085 570 46619321
Anaemia 297.51 21.85 16 66155 255763 46364128
Facial paralysis 296.88 21.85 202 65969 13048 46606843
Neck pain 289.46 21.85 374 65797 54932 46564959
Diplopia 282.03 21.85 228 65943 19177 46600714
Acute kidney injury 276.65 21.85 14 66157 235841 46384050
Neuromuscular toxicity 271.24 21.85 59 66112 96 46619795
Headache 252.20 21.85 1337 64834 477015 46142876
Rheumatoid arthritis 245.79 21.85 27 66144 240188 46379703
Pneumonia 241.73 21.85 116 66055 376204 46243687
Influenza like illness 238.88 21.85 348 65823 57222 46562669
Skin tightness 227.77 21.85 111 66060 3782 46616109
Toxicity to various agents 213.59 21.85 25 66146 211741 46408150
Arthralgia 204.38 21.85 133 66038 364470 46255421
Injection site rash 195.00 21.85 169 66002 15644 46604247
Hypotension 193.68 21.85 46 66125 232543 46387348
Drug interaction 192.81 21.85 29 66142 203065 46416826
Facial pain 187.03 21.85 123 66048 7502 46612389
Product administered at inappropriate site 182.97 21.85 82 66089 2301 46617590
Eyelid sensory disorder 182.16 21.85 35 66136 15 46619876
Completed suicide 179.89 21.85 6 66165 145914 46473977
Neutropenia 176.14 21.85 6 66165 143198 46476693
Fall 173.80 21.85 128 66043 328969 46290922
Death 168.96 21.85 137 66034 335411 46284480
Thrombocytopenia 164.37 21.85 3 66168 126578 46493313
Inappropriate schedule of product administration 162.26 21.85 313 65858 64700 46555191
Lagophthalmos 161.30 21.85 44 66127 251 46619640
Sepsis 150.53 21.85 11 66160 136003 46483888
Abdominal pain 145.78 21.85 72 66099 229959 46389932
Drug hypersensitivity 141.88 21.85 85 66086 243740 46376151
Incorrect dose administered 134.69 21.85 236 65935 45314 46574577
Vomiting 130.53 21.85 280 65891 452514 46167377
Periorbital swelling 130.35 21.85 54 66117 1244 46618647
Joint swelling 130.22 21.85 37 66134 166036 46453855
Oedema peripheral 130.10 21.85 33 66138 159673 46460218
Renal failure 126.22 21.85 9 66162 113585 46506306
Therapeutic response shortened 125.40 21.85 83 66088 5116 46614775
Injection site mass 124.64 21.85 129 66042 14911 46604980
Injection site erythema 122.49 21.85 303 65868 74124 46545767
Incorrect route of product administration 122.44 21.85 133 66038 16250 46603641
Haemoglobin decreased 120.96 21.85 19 66152 128930 46490961
Hypoaesthesia 120.88 21.85 407 65764 118462 46501429
Hyponatraemia 118.72 21.85 6 66165 101326 46518565
Head discomfort 116.38 21.85 105 66066 10246 46609645
General physical health deterioration 111.01 21.85 16 66155 115753 46504138
Infusion related reaction 109.67 21.85 9 66162 101199 46518692
Maternal exposure during pregnancy 108.72 21.85 10 66161 102539 46517352
Muscle twitching 107.71 21.85 118 66053 14554 46605337
Hypertension 106.60 21.85 74 66097 196282 46423609
Platelet count decreased 105.39 21.85 10 66161 100014 46519877
Cough 104.94 21.85 103 66068 230146 46389745
Drug intolerance 104.28 21.85 39 66132 147010 46472881
Periorbital oedema 101.59 21.85 72 66099 4963 46614928
Hypokalaemia 100.66 21.85 6 66165 88018 46531873
Asthenopia 100.06 21.85 51 66120 1915 46617976
Dry eye 100.06 21.85 165 66006 30157 46589734
Contraindicated product administered 99.51 21.85 3 66168 79944 46539947
Overdose 98.25 21.85 343 65828 101636 46518255
Condition aggravated 98.07 21.85 122 66049 244930 46374961
Disease progression 96.52 21.85 9 66162 91291 46528600
Gastrointestinal haemorrhage 95.96 21.85 3 66168 77370 46542521
Peripheral swelling 94.86 21.85 53 66118 158018 46461873
Pleural effusion 93.82 21.85 6 66165 82946 46536945
Pyrexia 93.60 21.85 224 65947 348578 46271313
Dehydration 93.59 21.85 55 66116 159485 46460406
Atrial fibrillation 93.30 21.85 17 66154 103573 46516318
Infection 92.12 21.85 37 66134 133555 46486336
Cardiac failure congestive 91.98 21.85 11 66160 91739 46528152
Renal impairment 91.81 21.85 3 66168 74369 46545522
Blepharospasm 90.32 21.85 50 66121 2224 46617667
Hepatic enzyme increased 89.36 21.85 7 66164 81780 46538111
Abdominal discomfort 88.83 21.85 52 66119 151113 46468778
Swelling of eyelid 88.31 21.85 40 66131 1151 46618740
Eye pain 88.13 21.85 149 66022 27791 46592100
Blood creatinine increased 87.99 21.85 5 66166 76398 46543493
Dysphonia 87.42 21.85 178 65993 38236 46581655
Lacrimation increased 87.20 21.85 110 66061 15751 46604140
Myocardial infarction 85.72 21.85 17 66154 97511 46522380
Pulmonary embolism 85.43 21.85 24 66147 108561 46511330
Product quality issue 84.48 21.85 168 66003 35480 46584411
White blood cell count decreased 84.32 21.85 27 66144 112204 46507687
Pain in extremity 83.84 21.85 149 66022 258531 46361360
Cardiac arrest 83.23 21.85 14 66157 90385 46529506
Muscle tightness 82.90 21.85 87 66084 10218 46609673
Aspartate aminotransferase increased 82.55 21.85 8 66163 78692 46541199
Nausea 81.61 21.85 606 65565 686848 45933043
Cardiac failure 81.60 21.85 9 66162 79939 46539952
Hypoaesthesia oral 81.14 21.85 87 66084 10472 46609419
Alanine aminotransferase increased 80.77 21.85 14 66157 88437 46531454
Decreased appetite 80.17 21.85 94 66077 193742 46426149
Weight increased 79.11 21.85 70 66101 164403 46455488
Product dose omission issue 78.35 21.85 74 66097 168446 46451445
Injection site bruising 77.41 21.85 162 66009 35474 46584417
Injection site urticaria 77.20 21.85 90 66081 11877 46608014
Nasopharyngitis 77.17 21.85 63 66108 153935 46465956
Bronchitis 76.99 21.85 27 66144 105952 46513939
Confusional state 75.76 21.85 69 66102 159823 46460068
Injection site paraesthesia 73.63 21.85 27 66144 443 46619448
Drug abuse 73.48 21.85 4 66167 63404 46556487
Psoriasis 72.75 21.85 12 66159 78592 46541299
Intentional overdose 72.54 21.85 5 66166 64939 46554952
Deep vein thrombosis 72.02 21.85 13 66158 79760 46540131
Arthropathy 71.89 21.85 16 66155 84684 46535207
Treatment failure 70.62 21.85 22 66149 93065 46526826
Systemic lupus erythematosus 70.04 21.85 6 66165 65174 46554717
Back pain 68.91 21.85 120 66051 209919 46409972
Facial spasm 68.36 21.85 28 66143 626 46619265
Injection site nodule 67.54 21.85 48 66123 3323 46616568
Arthritis 66.85 21.85 14 66157 77302 46542589
Urinary tract infection 66.81 21.85 132 66039 220134 46399757
Neuropathy peripheral 66.28 21.85 23 66148 90870 46529021
Product distribution issue 63.13 21.85 22 66149 309 46619582
Burning sensation 62.93 21.85 171 66000 44240 46575651
Leukopenia 61.99 21.85 11 66160 68332 46551559
Bradycardia 61.62 21.85 10 66161 66288 46553603
Coma 61.01 21.85 6 66165 58343 46561548
Respiratory failure 61.00 21.85 29 66142 94787 46525104
Hypoxia 60.92 21.85 3 66168 51835 46568056
Septic shock 60.41 21.85 6 66165 57887 46562004
Electrocardiogram QT prolonged 60.22 21.85 3 66168 51322 46568569
Speech disorder 59.19 21.85 147 66024 36020 46583871
Blood glucose increased 58.36 21.85 15 66156 71998 46547893
Thrombosis 58.01 21.85 6 66165 56063 46563828
Fatigue 57.99 21.85 568 65603 608129 46011762
Suicide attempt 56.66 21.85 6 66165 55030 46564861
Hypoglycaemia 55.76 21.85 6 66165 54343 46565548
Intentional product misuse 55.68 21.85 170 66001 46958 46572933
Lid sulcus deepened 54.83 21.85 13 66158 37 46619854
International normalised ratio increased 54.19 21.85 3 66168 46880 46573011
Pulmonary oedema 54.10 21.85 5 66166 51100 46568791
Stomatitis 53.88 21.85 15 66156 68282 46551609
Liver function test abnormal 53.65 21.85 3 66168 46484 46573407
Ocular discomfort 53.51 21.85 40 66131 2995 46616896
Mastication disorder 53.41 21.85 34 66137 1960 46617931
Chronic obstructive pulmonary disease 52.88 21.85 9 66162 57624 46562267
Injection site oedema 52.75 21.85 24 66147 698 46619193
Exposure during pregnancy 52.07 21.85 46 66125 108166 46511725
Paralysis 51.98 21.85 63 66108 8658 46611233
Cardio-respiratory arrest 51.42 21.85 11 66160 59858 46560033
Abnormal sensation in eye 50.31 21.85 31 66140 1687 46618204
Central nervous system function test abnormal 50.04 21.85 9 66162 0 46619891
Photophobia 49.13 21.85 80 66091 14464 46605427
Pain 48.79 21.85 437 65734 476511 46143380
Injection site discomfort 48.05 21.85 40 66131 3502 46616389
C-reactive protein increased 47.87 21.85 12 66159 58578 46561313
Eyelid pain 47.70 21.85 17 66154 256 46619635
Product reconstitution quality issue 47.68 21.85 12 66159 47 46619844
Constipation 47.22 21.85 111 66060 173986 46445905
Throat tightness 45.01 21.85 94 66077 20545 46599346
Somnolence 44.72 21.85 97 66074 156424 46463467
Manufacturing product shipping issue 44.51 21.85 12 66159 65 46619826
Neutrophil count decreased 44.02 21.85 5 66166 43421 46576470
Eye discharge 43.98 21.85 44 66127 4884 46615007
Mucosal inflammation 43.52 21.85 3 66168 38973 46580918
Extraocular muscle paresis 43.44 21.85 14 66157 152 46619739
Chronic kidney disease 43.26 21.85 4 66167 40867 46579024
Oxygen saturation decreased 43.20 21.85 22 66149 69142 46550749
Erythema of eyelid 43.17 21.85 29 66142 1832 46618059
Osteoporosis 42.91 21.85 4 66167 40604 46579287
Injection site haemorrhage 42.49 21.85 92 66079 20617 46599274
Therapeutic product effect decreased 42.48 21.85 230 65941 82371 46537520
Strabismus 42.18 21.85 28 66143 1734 46618157
Abdominal distension 41.98 21.85 26 66145 73325 46546566
Paraesthesia 41.55 21.85 297 65874 117140 46502751
Diabetes mellitus 41.39 21.85 10 66161 50055 46569836
Eye pruritus 40.94 21.85 66 66105 11832 46608059
Fluid retention 40.66 21.85 11 66160 51035 46568856
Agitation 40.43 21.85 14 66157 55401 46564490
Tension headache 40.06 21.85 32 66139 2642 46617249
Osteoarthritis 39.84 21.85 19 66152 62006 46557885
Weight decreased 39.66 21.85 159 66012 210690 46409201
Injection site hypoaesthesia 39.51 21.85 16 66155 347 46619544
Madarosis 39.45 21.85 27 66144 1759 46618132
Depression 38.90 21.85 118 66053 169986 46449905
Eyelid disorder 38.50 21.85 23 66148 1183 46618708
Glossodynia 38.42 21.85 8 66163 44365 46575526
Asthma 38.22 21.85 44 66127 91498 46528393
Accidental exposure to product 38.05 21.85 89 66082 20992 46598899
Cataract 37.69 21.85 9 66162 45406 46574485
Abdominal pain upper 37.54 21.85 95 66076 145210 46474681
Rhabdomyolysis 37.45 21.85 7 66164 41902 46577989
Product packaging issue 37.11 21.85 21 66150 975 46618916
Mental status changes 37.11 21.85 5 66166 38083 46581808
Lower respiratory tract infection 36.75 21.85 16 66155 55073 46564818
Cerebrovascular accident 36.60 21.85 54 66117 100985 46518906
Depressed level of consciousness 36.50 21.85 11 66160 47558 46572333
Muscle contractions involuntary 36.48 21.85 27 66144 1991 46617900
Haematochezia 36.34 21.85 5 66166 37488 46582403
Encephalopathy 36.33 21.85 3 66168 33586 46586305
White blood cell count increased 36.23 21.85 9 66162 44210 46575681
Dyspnoea exertional 36.18 21.85 13 66158 50276 46569615
Blood pressure increased 35.76 21.85 79 66092 126587 46493304
Femur fracture 35.70 21.85 5 66166 36992 46582899
Urticaria 35.45 21.85 287 65884 117605 46502286
Muscle atrophy 35.29 21.85 43 66128 5941 46613950
Epistaxis 35.15 21.85 24 66147 64281 46555610
Lung disorder 35.12 21.85 9 66162 43295 46576596
Drug effect less than expected 35.03 21.85 10 66161 69 46619822
Torticollis 35.03 21.85 25 66146 1742 46618149
Product temperature excursion issue 34.60 21.85 7 66164 6 46619885
Blood alkaline phosphatase increased 34.59 21.85 7 66164 39602 46580289
Blood bilirubin increased 34.49 21.85 4 66167 34180 46585711
Hypoaesthesia eye 34.43 21.85 10 66161 74 46619817
Gastrointestinal disorder 34.25 21.85 21 66150 59555 46560336
Sinusitis 34.17 21.85 84 66087 129684 46490207
Colitis 33.89 21.85 6 66165 37341 46582550
Gamma-glutamyltransferase increased 33.88 21.85 3 66168 31737 46588154
Delirium 33.74 21.85 6 66165 37222 46582669
Pancreatitis 33.64 21.85 10 66161 43617 46576274
Hepatic failure 33.49 21.85 4 66167 33412 46586479
Haemorrhage 33.46 21.85 18 66153 54851 46565040
Injection site indentation 33.29 21.85 11 66160 130 46619761
Lip swelling 33.22 21.85 95 66076 25300 46594591
Eye irritation 33.16 21.85 73 66098 16541 46603350
Impaired healing 33.13 21.85 6 66165 36737 46583154
Chest pain 33.13 21.85 133 66038 176191 46443700
Hospitalisation 32.89 21.85 25 66146 63360 46556531
Wound 32.66 21.85 10 66161 42792 46577099
Product use issue 31.98 21.85 53 66118 94591 46525300
Blood pressure decreased 31.69 21.85 21 66150 57138 46562753
Liver disorder 31.66 21.85 7 66164 37239 46582652
Cutis laxa 31.47 21.85 11 66160 156 46619735
Cholelithiasis 31.44 21.85 8 66163 38673 46581218
Choking 30.94 21.85 48 66123 8328 46611563
Application site acne 30.93 21.85 6 66165 3 46619888
Rectal haemorrhage 30.93 21.85 8 66163 38247 46581644
Diverticulitis 30.66 21.85 5 66166 33034 46586857
Facial discomfort 30.62 21.85 7 66164 16 46619875
Pregnancy 30.30 21.85 96 66075 27041 46592850
Injection site anaesthesia 30.21 21.85 8 66163 40 46619851
Red blood cell count decreased 30.13 21.85 5 66166 32618 46587273
Jaundice 30.06 21.85 3 66168 28842 46591049
Ocular hyperaemia 30.04 21.85 78 66093 19632 46600259
Haematemesis 30.01 21.85 3 66168 28803 46591088
Lip disorder 29.86 21.85 19 66152 1094 46618797
Skin disorder 29.82 21.85 84 66087 22179 46597712
Nerve injury 29.65 21.85 45 66126 7660 46612231
Blood cholesterol increased 29.38 21.85 10 66161 40003 46579888
Eye contusion 29.12 21.85 21 66150 1487 46618404
Haematocrit decreased 28.98 21.85 7 66164 35050 46584841
Syncope 28.25 21.85 67 66104 104736 46515155
Diaphragmatic rupture 28.22 21.85 11 66160 215 46619676
Malaise 28.16 21.85 317 65854 330915 46288976
Eyelid thickening 27.81 21.85 8 66163 57 46619834
Intranasal hypoaesthesia 27.80 21.85 5 66166 0 46619891
Tachycardia 27.40 21.85 63 66108 99559 46520332
Hypocalcaemia 27.36 21.85 3 66168 26782 46593109
Oedema 27.18 21.85 33 66138 67038 46552853
Cellulitis 27.01 21.85 36 66135 70252 46549639
Psoriatic arthropathy 26.87 21.85 9 66162 36370 46583521
Gastrooesophageal reflux disease 26.66 21.85 40 66131 74304 46545587
Occupational exposure to product 26.65 21.85 21 66150 1700 46618191
Haemoptysis 26.58 21.85 3 66168 26186 46593705
Treatment noncompliance 26.49 21.85 5 66166 29726 46590165
Skin indentation 26.47 21.85 6 66165 13 46619878
Intestinal obstruction 26.43 21.85 3 66168 26072 46593819
Injection site pruritus 26.36 21.85 119 66052 39624 46580267
Pericardial effusion 25.74 21.85 3 66168 25540 46594351
Drug withdrawal syndrome 25.73 21.85 4 66167 27380 46592511
Drooling 25.64 21.85 27 66144 3182 46616709
Erythema 25.50 21.85 312 65859 142508 46477383
Dermatochalasis 25.46 21.85 5 66166 3 46619888
Blepharochalasis 25.46 21.85 5 66166 3 46619888
Flatulence 25.43 21.85 5 66166 28873 46591018
Alopecia 25.42 21.85 131 66040 162283 46457608
Blood pressure systolic increased 25.32 21.85 5 66166 28782 46591109
Acute myocardial infarction 25.20 21.85 7 66164 31917 46587974
Angina pectoris 24.96 21.85 4 66167 26771 46593120
Pancreatitis acute 24.87 21.85 3 66168 24869 46595022
Cerebral haemorrhage 24.80 21.85 5 66166 28366 46591525
Muscle spasms 24.66 21.85 275 65896 122838 46497053
Prescribed overdose 24.45 21.85 49 66122 10400 46609491
Dry mouth 24.33 21.85 147 66024 54779 46565112
Upper respiratory tract infection 23.97 21.85 33 66138 63523 46556368
Patient dissatisfaction with treatment 23.96 21.85 7 66164 53 46619838
Product quality control issue 23.94 21.85 6 66165 23 46619868
Blood potassium decreased 23.93 21.85 12 66159 38051 46581840
Injection site pallor 23.85 21.85 7 66164 54 46619837
Hepatic steatosis 23.79 21.85 3 66168 24039 46595852
Product supply issue 23.59 21.85 15 66156 863 46619028
Ophthalmoplegia 23.46 21.85 15 66156 871 46619020
Injury 23.31 21.85 17 66154 44010 46575881
Application site papules 23.09 21.85 7 66164 61 46619830
Wheezing 23 21.85 25 66146 53361 46566530
Cerebral infarction 22.92 21.85 3 66168 23363 46596528
Sensation of foreign body 22.90 21.85 28 66143 3883 46616008
Eyelids pruritus 22.77 21.85 13 66158 614 46619277
Dyspepsia 22.52 21.85 39 66132 68433 46551458
Skin ulcer 22.33 21.85 9 66162 32449 46587442
Eyelid contusion 22.24 21.85 4 66167 0 46619891
Dyspnoea 22.20 21.85 559 65612 514989 46104902
Procedural anxiety 22.09 21.85 12 66159 514 46619377
Unresponsive to stimuli 22.01 21.85 9 66162 32165 46587726
Hallucination 21.96 21.85 23 66148 49928 46569963

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 2203.01 25.37 1281 7295 339106 29604796
Off label use 1012.31 25.37 708 7868 248582 29695320
Product preparation error 693.67 25.37 147 8429 1559 29942343
Therapeutic response decreased 608.80 25.37 237 8339 24112 29919790
Injection site pain 370.09 25.37 178 8398 30132 29913770
Eyelid ptosis 365.70 25.37 110 8466 5078 29938824
Wrong technique in product usage process 353.43 25.37 174 8402 30981 29912921
Multiple use of single-use product 269.53 25.37 44 8532 80 29943822
Dysphagia 251.65 25.37 172 8404 56526 29887376
Muscular weakness 200.47 25.37 157 8419 63488 29880414
Migraine 116.88 25.37 62 8514 12812 29931090
Botulism 107.94 25.37 22 8554 188 29943714
Product storage error 104.27 25.37 46 8530 6345 29937557
Neuromuscular toxicity 98.38 25.37 16 8560 28 29943874
Product preparation issue 70.93 25.37 15 8561 156 29943746
Injection site swelling 59.75 25.37 35 8541 8745 29935157
Poor quality product administered 58.94 25.37 21 8555 1648 29942254
Facial paresis 58 25.37 24 8552 2826 29941076
Acute kidney injury 54.79 25.37 7 8569 273835 29670067
Brow ptosis 50.11 25.37 7 8569 0 29943902
Drug ineffective for unapproved indication 45.71 25.37 32 8544 10848 29933054
Therapeutic product effect decreased 42.76 25.37 47 8529 29029 29914873
Anaemia 42.34 25.37 5 8571 207987 29735915
Headache 42.10 25.37 131 8445 182175 29761727
Diplopia 41.10 25.37 33 8543 13739 29930163
Neck pain 34.57 25.37 36 8540 20908 29922994
Toxicity to various agents 32.04 25.37 6 8570 177177 29766725
Drug interaction 31.64 25.37 9 8567 199559 29744343
Eyelid oedema 28.87 25.37 18 8558 5027 29938875
Injection site rash 26.45 25.37 15 8561 3524 29940378
Muscle spasticity 25.94 25.37 17 8559 5171 29938731

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175770 Acetylcholine Release Inhibitors
FDA EPC N0000175771 Acetylcholine Release Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rhytidectomy of glabellar frown lines indication 14667004

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Synaptosomal-associated protein 25 Cytosolic other BLOCKER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
E211KPY694 UNII
93384-43-1 SECONDARY_CAS_RN
4020561 VANDF
C0006050 UMLSCUI
CHEBI:3160 CHEBI
CHEMBL4297862 ChEMBL_ID
DB00083 DRUGBANK_ID
D00783 KEGG_DRUG
1712 RXNORM
4295 MMSL
d01227 MMSL
108890005 SNOMEDCT_US
427412002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BOTOX HUMAN PRESCRIPTION DRUG LABEL 1 0023-1145 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRADERMAL BLA 30 sections
BOTOX Cosmetic HUMAN PRESCRIPTION DRUG LABEL 1 0023-3919 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 30 sections
BOTOX HUMAN PRESCRIPTION DRUG LABEL 1 0023-3921 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 200 [USPU] INTRADERMAL BLA 30 sections
BOTOX Cosmetic HUMAN PRESCRIPTION DRUG LABEL 1 0023-9232 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 30 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1605 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1610 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-1620 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 200 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-4110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 0259-4150 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 0299-5962 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 U INTRAMUSCULAR BLA 33 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 15054-0500 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 U INTRAMUSCULAR BLA 31 sections
Dysport HUMAN PRESCRIPTION DRUG LABEL 1 15054-0530 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 U INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-160 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-161 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Xeomin HUMAN PRESCRIPTION DRUG LABEL 1 46783-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 [USPU] INTRAMUSCULAR BLA 31 sections
Jeuveau HUMAN PRESCRIPTION DRUG LABEL 1 72301-595 POWDER 100 [USPU] INTRAMUSCULAR BLA 28 sections